RS59906B1 - Pirimidindionska jedinjenja protiv srčanih stanja - Google Patents

Pirimidindionska jedinjenja protiv srčanih stanja

Info

Publication number: RS59906B1
Authority: RS; Serbia
Prior art keywords: compounds against; cardiac conditions; against cardiac; pyrimidinedione compounds; pyrimidinedione
Prior art date: 2013-06-21

Application number

RS20200149A

Other languages

English (en)

Inventor

Johan Oslob

Robert Anderson

Danielle Aubele

Marc Evanchik

Jonathan Charles Fox

Brian Kane

Puping Lu

Robert Mcdowell

Hector Rodriguez

Yonghong Song

Arvinder Sran

Original Assignee

Myokardia Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-06-21

Filing date

2014-06-19

Publication date

2020-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51177189&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS59906(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-06-19 Application filed by Myokardia Inc filed Critical Myokardia Inc

2020-03-31 Publication of RS59906B1 publication Critical patent/RS59906B1/sr

Links

230000000747 cardiac effect Effects 0.000 title 1
150000008512 pyrimidinediones Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

RS20200149A 2013-06-21 2014-06-19 Pirimidindionska jedinjenja protiv srčanih stanja RS59906B1 (sr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201361838088P	2013-06-21	2013-06-21
US201461939655P	2014-02-13	2014-02-13
US201461981366P	2014-04-18	2014-04-18
EP14738986.0A EP3010910B1 (en)	2013-06-21	2014-06-19	Pyrimidinedione compounds against cardiac conditions
PCT/US2014/043192 WO2014205223A1 (en)	2013-06-21	2014-06-19	Pyrimidinedione compounds against cardiac conditions

Publications (1)

Publication Number	Publication Date
RS59906B1 true RS59906B1 (sr)	2020-03-31

Family

ID=51177189

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20200149A RS59906B1 (sr)	2013-06-21	2014-06-19	Pirimidindionska jedinjenja protiv srčanih stanja

Country Status (38)

Country	Link
US (7)	US9181200B2 (sr)
EP (2)	EP3010910B1 (sr)
JP (4)	JP6603213B2 (sr)
KR (4)	KR20220020410A (sr)
CN (2)	CN105473576B (sr)
AU (5)	AU2014281408B2 (sr)
BR (1)	BR112015031864B1 (sr)
CA (1)	CA2915967C (sr)
CL (1)	CL2015003689A1 (sr)
CR (1)	CR20160032A (sr)
CY (1)	CY1122964T1 (sr)
DK (1)	DK3010910T3 (sr)
DO (1)	DOP2015000300A (sr)
EA (2)	EA030846B1 (sr)
ES (1)	ES2773250T3 (sr)
FI (1)	FIC20230036I1 (sr)
FR (1)	FR23C1047I1 (sr)
GT (1)	GT201500348A (sr)
HK (1)	HK1223930A1 (sr)
HR (1)	HRP20200379T1 (sr)
HU (2)	HUE047566T2 (sr)
IL (5)	IL302299A (sr)
LT (1)	LT3010910T (sr)
MX (3)	MX2015017865A (sr)
MY (1)	MY190860A (sr)
NL (1)	NL301253I2 (sr)
NO (1)	NO2023043I1 (sr)
PE (1)	PE20160208A1 (sr)
PH (1)	PH12015502794A1 (sr)
PL (1)	PL3010910T3 (sr)
PT (1)	PT3010910T (sr)
RS (1)	RS59906B1 (sr)
SG (2)	SG11201510163TA (sr)
SI (1)	SI3010910T1 (sr)
TN (1)	TN2015000553A1 (sr)
UA (1)	UA117929C2 (sr)
WO (1)	WO2014205223A1 (sr)
ZA (1)	ZA201508959B (sr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2822381C (en)	2010-12-23	2019-04-02	Foundry Newco Xii, Inc.	System for mitral valve repair and replacement
WO2012177942A2 (en)	2011-06-21	2012-12-27	Hanson Gifford, Iii	Prosthetic heart valve devices and associated systems and methods
US10016271B2 (en)	2011-10-19	2018-07-10	Twelve, Inc.	Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US9039757B2 (en)	2011-10-19	2015-05-26	Twelve, Inc.	Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US11202704B2 (en)	2011-10-19	2021-12-21	Twelve, Inc.	Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
EP4252714A3 (en)	2011-10-19	2023-12-20	Twelve, Inc.	Device for heart valve replacement
US9579198B2 (en)	2012-03-01	2017-02-28	Twelve, Inc.	Hydraulic delivery systems for prosthetic heart valve devices and associated methods
US9199945B2 (en) *	2013-06-21	2015-12-01	MyoKardia, Inc.	Cycloalkyl-substituted pyrimidinedione compounds
BR112015031864B1 (pt) *	2013-06-21	2022-02-15	Myokardia, Inc	Compostos de pirimidinadiona contra as condições cardíacas, composição farmacêutica e uso
TWI741478B (zh)	2014-02-13	2021-10-01	美商英塞特控股公司	作為lsd1抑制劑之環丙胺
US9346776B2 (en)	2014-02-13	2016-05-24	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound
US9527835B2 (en)	2014-02-13	2016-12-27	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
US9428470B2 (en)	2014-02-13	2016-08-30	Takeda Pharmaceutical Company Limited	Heterocyclic compound
BR112016018555B1 (pt)	2014-02-13	2024-01-23	Incyte Holdings Corporation	Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
US9695167B2 (en)	2014-07-10	2017-07-04	Incyte Corporation	Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TWI687419B (zh)	2014-07-10	2020-03-11	美商英塞特公司	作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
AU2016243939B2 (en)	2015-04-03	2020-09-03	Incyte Holdings Corporation	Heterocyclic compounds as LSD1 inhibitors
MY189367A (en)	2015-08-12	2022-02-08	Incyte Corp	Salts of an lsd1 inhibitor
CN106432222A (zh) *	2016-09-19	2017-02-22	丹诺医药(苏州）有限公司	8‑氯‑1‑环丙基‑7‑氟‑9‑甲基‑4‑氧‑4‑氢‑喹嗪‑3‑羧酸酯及其制备方法
CN106946851B (zh) *	2017-03-14	2019-11-12	牡丹江医学院	一种用于预防和治疗肾结石的药物
US10575950B2 (en)	2017-04-18	2020-03-03	Twelve, Inc.	Hydraulic systems for delivering prosthetic heart valve devices and associated methods
US10646338B2 (en)	2017-06-02	2020-05-12	Twelve, Inc.	Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods
RU2020109345A (ru) *	2017-08-04	2021-09-06	Миокардиа, Инк.	Применение мавакамтена для лечения гипертрофической кардиомиопатии
MX2020007532A (es)	2018-01-19	2020-09-09	Cytokinetics Inc	Inhibidores de sarcomero cardiaco.
US11964967B2 (en)	2018-06-26	2024-04-23	Cytokinetics, Inc.	Cardiac sarcomere inhibitors
EP3843842A1 (en) *	2018-08-31	2021-07-07	Cytokinetics, Inc.	Cardiac sarcomere inhibitors
US10968200B2 (en)	2018-08-31	2021-04-06	Incyte Corporation	Salts of an LSD1 inhibitor and processes for preparing the same
CN113056465A (zh)	2018-10-29	2021-06-29	迈奥卡迪亚公司	经四氢吡喃(thp)取代的双环嘧啶二酮化合物
WO2020151605A1 (zh) *	2019-01-25	2020-07-30	青岛吉澳医药科技有限公司	氘代苯甲氨嘧啶二酮衍生物及其用途
CN110698415B (zh) *	2019-10-21	2023-05-09	上海先行医药开发有限公司	一种肌球蛋白抑制剂及其制备方法和用途
CA3165995A1 (en) *	2020-01-28	2021-08-05	Lorena KORDIC	Solid state forms of mavacamten and process for preparation thereof
AU2021381664A1 (en) *	2020-11-20	2023-06-15	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Triazine dione derivative, preparation method therefor and application thereof in medicine
TW202227402A (zh) *	2020-11-24	2022-07-16	大陸商江蘇恆瑞醫藥股份有限公司	嘧啶二酮類衍生物、其製備方法及其在醫藥上的應用
CN114539229A (zh) *	2020-11-24	2022-05-27	江苏恒瑞医药股份有限公司	嘧啶二酮类衍生物、其制备方法及其在医药上的应用
MX2023008810A (es) *	2021-02-01	2023-08-04	Dr Reddys Laboratories Ltd	Proceso de preparacion de mavacamten y formas en estado solido del mismo.
US11919909B2 (en)	2021-03-04	2024-03-05	Cytokinetics, Inc.	Cardiac sarcomere inhibitors
CN112939876A (zh) *	2021-03-10	2021-06-11	杭州科巢生物科技有限公司	Mavacamten的晶型I及其制备方法
WO2022189599A1 (en)	2021-03-12	2022-09-15	Sandoz Ag	Crystalline forms of mavacamten for the treatment of hcm
TW202302541A (zh) *	2021-03-17	2023-01-16	美商翰森生物有限責任公司	含氮雜環酮、其製備方法和醫藥用途
JPWO2023286719A1 (sr) *	2021-07-13	2023-01-19
CN116410143A (zh) *	2021-12-29	2023-07-11	杭州奥默医药股份有限公司	一种多取代脲嘧啶衍生物及其制备方法和应用
WO2023199258A1 (en)	2022-04-13	2023-10-19	Teva Pharmaceuticals International Gmbh	Solid state forms of mavacamten and process for preparation thereof
WO2023211872A1 (en)	2022-04-26	2023-11-02	MyoKardia, Inc.	Methods of administering myosin inhibitors
WO2023222103A1 (zh) *	2022-05-20	2023-11-23	江苏恒瑞医药股份有限公司	一种三嗪二酮类衍生物的晶型及制备方法
WO2024056096A1 (zh) *	2022-09-16	2024-03-21	江苏豪森药业集团有限公司	一种含氮杂环酮化合物的晶型及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1280877B (de)	1960-11-16	1968-10-24	Robugen Gmbh	Verfahren zur Herstellung von in 1-Stellung substituierten 4-Aminouracilen
JPS61205261A (ja)	1985-03-08	1986-09-11	Sagami Chem Res Center	６―置換―５―フルオロウラシル誘導体
US5008267A (en)	1988-10-29	1991-04-16	Mitsui Toatsu Chemicals, Incorporated	Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same
FR2659656B1 (fr)	1990-03-15	1994-09-09	Sanofi Sa	Derives de pyrimidinedione-2,4 et medicaments les contenant.
JPH06128238A (ja)	1992-10-20	1994-05-10	Mitsui Toatsu Chem Inc	新規ピリミジンジオン誘導体
US5516905A (en)	1994-08-30	1996-05-14	University Of Massachusetts Medical Center	Antibiotic compounds and methods to treat gram-positive bacterial and mycoplasmal infections
DE59903953D1 (de)	1998-06-26	2003-02-13	Crompton Vinyl Additives Gmbh	Neue NH2-modifizierte 6-Aminouracile als Stabilisatoren für halogenhaltige Polymere
US7202051B1 (en)	1999-05-18	2007-04-10	Cytokinetics, Inc.	Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7416856B2 (en)	1999-05-18	2008-08-26	Cytokinetics, Inc.	High sensitivity assay for detection of nucleoside diphosphate production
AU2247701A (en)	1999-10-21	2001-04-30	Merck & Co., Inc.	Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
US6495337B1 (en)	2000-03-29	2002-12-17	Cytokinetics, Inc.	High throughput sarcomeric assay
US20030114414A1 (en)	2001-06-15	2003-06-19	Chengxin Zhi	Methods for synthesizing substituted pyrimidines
AU2002344813A1 (en)	2001-06-15	2003-01-02	University Of Massachusetts	Methods for synthesizing substituted pyrimidines
EP1553949B1 (en) *	2002-08-13	2007-04-18	Warner-Lambert Company LLC	Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
BRPI0418639B8 (pt)	2004-03-15	2021-05-25	Takeda Pharmaceutical	compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos
US20060194821A1 (en)	2005-02-18	2006-08-31	The Brigham And Women's Hospital, Inc.	Compounds inhibiting the aggregation of superoxide dismutase-1
AU2008345225A1 (en) *	2007-12-21	2009-07-09	University Of Rochester	Method for altering the lifespan of eukaryotic organisms
GB0908193D0 (en) *	2009-05-13	2009-06-24	Albright Patents	Treatment of disease state
BR112015031864B1 (pt) *	2013-06-21	2022-02-15	Myokardia, Inc	Compostos de pirimidinadiona contra as condições cardíacas, composição farmacêutica e uso
US9199945B2 (en) *	2013-06-21	2015-12-01	MyoKardia, Inc.	Cycloalkyl-substituted pyrimidinedione compounds

2014
- 2014-06-19 BR BR112015031864-9A patent/BR112015031864B1/pt active IP Right Grant
- 2014-06-19 ES ES14738986T patent/ES2773250T3/es active Active
- 2014-06-19 JP JP2016521578A patent/JP6603213B2/ja active Active
- 2014-06-19 KR KR1020227003283A patent/KR20220020410A/ko not_active IP Right Cessation
- 2014-06-19 WO PCT/US2014/043192 patent/WO2014205223A1/en active Application Filing
- 2014-06-19 SG SG11201510163TA patent/SG11201510163TA/en unknown
- 2014-06-19 CN CN201480046057.3A patent/CN105473576B/zh active Active
- 2014-06-19 KR KR1020217029573A patent/KR102359158B1/ko active IP Right Grant
- 2014-06-19 PL PL14738986T patent/PL3010910T3/pl unknown
- 2014-06-19 IL IL302299A patent/IL302299A/en unknown
- 2014-06-19 TN TN2015000553A patent/TN2015000553A1/en unknown
- 2014-06-19 EP EP14738986.0A patent/EP3010910B1/en active Active
- 2014-06-19 PE PE2015002629A patent/PE20160208A1/es unknown
- 2014-06-19 EP EP20155100.9A patent/EP3702352A1/en active Pending
- 2014-06-19 CA CA2915967A patent/CA2915967C/en active Active
- 2014-06-19 PT PT147389860T patent/PT3010910T/pt unknown
- 2014-06-19 HU HUE14738986A patent/HUE047566T2/hu unknown
- 2014-06-19 MX MX2015017865A patent/MX2015017865A/es unknown
- 2014-06-19 SG SG10201803459TA patent/SG10201803459TA/en unknown
- 2014-06-19 IL IL310829A patent/IL310829A/en unknown
- 2014-06-19 CN CN201811208548.XA patent/CN109384729B/zh active Active
- 2014-06-19 MY MYPI2015704457A patent/MY190860A/en unknown
- 2014-06-19 LT LTEP14738986.0T patent/LT3010910T/lt unknown
- 2014-06-19 EA EA201690066A patent/EA030846B1/ru unknown
- 2014-06-19 AU AU2014281408A patent/AU2014281408B2/en active Active
- 2014-06-19 KR KR1020167001045A patent/KR102304121B1/ko active IP Right Grant
- 2014-06-19 US US14/309,381 patent/US9181200B2/en active Active
- 2014-06-19 SI SI201431491T patent/SI3010910T1/sl unknown
- 2014-06-19 RS RS20200149A patent/RS59906B1/sr unknown
- 2014-06-19 UA UAA201600450A patent/UA117929C2/uk unknown
- 2014-06-19 EA EA201891009A patent/EA201891009A1/ru unknown
- 2014-06-19 KR KR1020237033462A patent/KR20230144117A/ko not_active Application Discontinuation
- 2014-06-19 DK DK14738986.0T patent/DK3010910T3/da active
- 2014-06-19 MX MX2021005326A patent/MX2021005326A/es unknown
2015
- 2015-10-14 US US14/883,152 patent/US9585883B2/en active Active
- 2015-12-08 ZA ZA2015/08959A patent/ZA201508959B/en unknown
- 2015-12-14 DO DO2015000300A patent/DOP2015000300A/es unknown
- 2015-12-16 PH PH12015502794A patent/PH12015502794A1/en unknown
- 2015-12-17 IL IL243222A patent/IL243222B/en active IP Right Grant
- 2015-12-17 GT GT201500348A patent/GT201500348A/es unknown
- 2015-12-18 MX MX2022014414A patent/MX2022014414A/es unknown
- 2015-12-21 CL CL2015003689A patent/CL2015003689A1/es unknown
2016
- 2016-01-15 CR CR20160032A patent/CR20160032A/es unknown
- 2016-10-24 HK HK16112177.2A patent/HK1223930A1/zh unknown
2017
- 2017-01-18 US US15/409,369 patent/US20170281626A1/en not_active Abandoned
2018
- 2018-02-15 US US15/897,549 patent/US20180311242A1/en not_active Abandoned
- 2018-11-15 AU AU2018264088A patent/AU2018264088A1/en not_active Abandoned
2019
- 2019-10-09 JP JP2019185576A patent/JP6980734B2/ja active Active
2020
- 2020-03-06 HR HRP20200379TT patent/HRP20200379T1/hr unknown
- 2020-04-15 CY CY20201100354T patent/CY1122964T1/el unknown
- 2020-06-05 US US16/893,500 patent/US20200297726A1/en not_active Abandoned
- 2020-06-26 AU AU2020204271A patent/AU2020204271B2/en active Active
- 2020-07-05 IL IL275837A patent/IL275837B/en unknown
2021
- 2021-01-13 US US17/147,821 patent/US20210346379A1/en not_active Abandoned
- 2021-08-30 IL IL285971A patent/IL285971A/en unknown
- 2021-11-17 JP JP2021186772A patent/JP7376556B2/ja active Active
2022
- 2022-04-06 AU AU2022202298A patent/AU2022202298A1/en not_active Abandoned
2023
- 2023-01-27 US US18/160,393 patent/US20230165860A1/en active Pending
- 2023-10-26 JP JP2023183708A patent/JP2024010108A/ja active Pending
- 2023-12-01 FI FIC20230036C patent/FIC20230036I1/fi unknown
- 2023-12-01 NO NO2023043C patent/NO2023043I1/no unknown
- 2023-12-04 FR FR23C1047C patent/FR23C1047I1/fr active Active
- 2023-12-11 HU HUS2300042C patent/HUS2300042I1/hu unknown
- 2023-12-12 NL NL301253C patent/NL301253I2/nl unknown
2024
- 2024-04-16 AU AU2024202464A patent/AU2024202464A1/en active Pending

Also Published As

Publication number	Publication date
WO2014205223A1 (en)	2014-12-24
CR20160032A (es)	2016-04-01
US20180311242A1 (en)	2018-11-01
CN105473576A (zh)	2016-04-06
CA2915967C (en)	2021-07-20
HUE047566T2 (hu)	2020-04-28
HUS2300042I1 (hu)	2024-01-28
UA117929C2 (uk)	2018-10-25
JP2020019809A (ja)	2020-02-06
EA030846B1 (ru)	2018-10-31
PE20160208A1 (es)	2016-05-04
EA201690066A1 (ru)	2016-05-31
SG11201510163TA (en)	2016-01-28
US20140378464A1 (en)	2014-12-25
MY190860A (en)	2022-05-12
JP2022036966A (ja)	2022-03-08
BR112015031864B1 (pt)	2022-02-15
US9585883B2 (en)	2017-03-07
AU2022202298A1 (en)	2022-04-28
JP6980734B2 (ja)	2021-12-15
NL301253I2 (nl)	2024-01-10
IL243222A0 (en)	2016-02-29
FR23C1047I1 (fr)	2024-01-12
IL302299A (en)	2023-06-01
EP3010910B1 (en)	2020-02-05
KR102359158B1 (ko)	2022-02-08
GT201500348A (es)	2018-12-20
AU2020204271B2 (en)	2022-01-06
CL2015003689A1 (es)	2016-10-14
NL301253I1 (sr)	2023-12-13
SI3010910T1 (sl)	2020-04-30
KR20160026997A (ko)	2016-03-09
KR102304121B1 (ko)	2021-09-24
JP7376556B2 (ja)	2023-11-08
JP6603213B2 (ja)	2019-11-06
LT3010910T (lt)	2020-03-10
MX2021005326A (es)	2022-11-17
BR112015031864A2 (pt)	2017-07-25
AU2014281408A1 (en)	2016-01-21
IL285971A (en)	2021-10-31
KR20230144117A (ko)	2023-10-13
MX2015017865A (es)	2016-09-06
NO2023043I1 (no)	2023-12-01
IL275837B (en)	2021-09-30
KR20210118470A (ko)	2021-09-30
US20170281626A1 (en)	2017-10-05
CA2915967A1 (en)	2014-12-24
TN2015000553A1 (en)	2017-04-06
HK1223930A1 (zh)	2017-08-11
EA201891009A1 (ru)	2018-09-28
AU2014281408B2 (en)	2018-08-16
IL243222B (en)	2020-07-30
DOP2015000300A (es)	2016-03-15
US20160030428A1 (en)	2016-02-04
DK3010910T3 (da)	2020-02-17
MX2022014414A (es)	2022-12-07
IL310829A (en)	2024-04-01
ZA201508959B (en)	2022-09-28
CN109384729A (zh)	2019-02-26
PL3010910T3 (pl)	2020-07-27
NZ715456A (en)	2021-01-29
CN109384729B (zh)	2023-06-30
CN105473576B (zh)	2018-10-30
AU2024202464A1 (en)	2024-05-02
IL275837A (en)	2020-08-31
AU2020204271A1 (en)	2020-07-16
AU2018264088A1 (en)	2018-12-06
HRP20200379T1 (hr)	2020-06-12
PT3010910T (pt)	2020-02-21
US9181200B2 (en)	2015-11-10
KR20220020410A (ko)	2022-02-18
SG10201803459TA (en)	2018-05-30
JP2024010108A (ja)	2024-01-23
CY1122964T1 (el)	2021-10-29
EP3702352A1 (en)	2020-09-02
US20230165860A1 (en)	2023-06-01
ES2773250T3 (es)	2020-07-10
US20200297726A1 (en)	2020-09-24
FIC20230036I1 (fi)	2023-12-01
US20210346379A1 (en)	2021-11-11
PH12015502794A1 (en)	2016-03-21
JP2016522263A (ja)	2016-07-28
EP3010910A1 (en)	2016-04-27

Publication	Publication Date	Title
HUS2300042I1 (hu)	2024-01-28	Pirimidindion vegyületek szívtörténések ellen
IL249517B (en)	2020-04-30	A compound that inhibits trk
AP2015008713A0 (en)	2015-09-30	Tetrahydropyrrolothiazine compounds
GB201303109D0 (en)	2013-04-10	Novel pyrimidine compounds
GB201302368D0 (en)	2013-03-27	Compound
HK1219100A1 (zh)	2017-03-24	吡啶基吡唑並喹啉化合物
AP3850A (en)	2016-09-30	Azetidinyloxyphenylpyrrolidine compounds
EP2947066A4 (en)	2016-06-22	PHENOXYALKYLAMINVERBINDUNG
GB201310626D0 (en)	2013-07-31	Rivetable attachment
PL2826522T3 (pl)	2018-12-31	Rozrusznik serca
GB201307331D0 (en)	2013-05-29	Compound
GB201408643D0 (en)	2014-07-02	Compound
GB201318631D0 (en)	2013-12-04	Composition - BioFresh AMB
GB201314777D0 (en)	2013-10-02	Ablutionary attachment
GB201322438D0 (en)	2014-02-05	Compound
GB201315772D0 (en)	2013-10-16	Compound
GB201305634D0 (en)	2013-05-15	Compound
GB201304250D0 (en)	2013-04-24	Compound
GB201301585D0 (en)	2013-03-13	Compound